[1]
2024. Establishing a Risk Model for Diabetic Nephropathy and Addressing the Therapeutic Effect of  Combined Epalrestat- Dapagliflozin Regimen. Iranian Journal of Kidney Diseases. 18, 05 (Oct. 2024). DOI:https://doi.org/10.52547/ax1vqh41.